Kura Oncology (NASDAQ:KURA) Insider Teresa Brophy Bair Sells 8,804 Shares

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 8,804 shares of the firm’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $11.18, for a total value of $98,428.72. Following the sale, the insider directly owned 188,139 shares of the company’s stock, valued at $2,103,394.02. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Teresa Brophy Bair also recently made the following trade(s):

• On Monday, September 29th, Teresa Brophy Bair sold 8,805 shares of Kura Oncology stock. The stock was sold at an average price of $8.94, for a total value of $78,716.70.

Kura Oncology Trading Up 4.9%

NASDAQ:KURA traded up $0.52 during mid-day trading on Friday, reaching $11.20. 4,478,689 shares of the company were exchanged, compared to its average volume of 2,241,571. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $16.68. The company has a fifty day moving average of $9.46 and a 200 day moving average of $7.48. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The company had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million. As a group, equities analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KURA. Cerity Partners LLC acquired a new position in shares of Kura Oncology in the 1st quarter valued at approximately $210,000. CWM LLC increased its holdings in Kura Oncology by 892.8% in the 1st quarter. CWM LLC now owns 28,353 shares of the company’s stock worth $187,000 after purchasing an additional 25,497 shares in the last quarter. Jennison Associates LLC grew its holdings in Kura Oncology by 93.8% during the 1st quarter. Jennison Associates LLC now owns 138,532 shares of the company’s stock worth $914,000 after acquiring an additional 67,035 shares during the last quarter. 1492 Capital Management LLC raised its position in Kura Oncology by 25.4% during the 1st quarter. 1492 Capital Management LLC now owns 429,746 shares of the company’s stock worth $2,836,000 after purchasing an additional 87,148 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Kura Oncology by 23.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,784 shares of the company’s stock worth $216,000 after acquiring an additional 6,154 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages recently commented on KURA. JMP Securities reiterated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research report on Monday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Guggenheim assumed coverage on Kura Oncology in a report on Thursday, September 4th. They issued a “neutral” rating for the company. UBS Group raised their price target on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research note on Friday. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.11.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.